Form 4: Entrada Therapeutics' Chief Scientific Officer, Natarajan Sethuraman, Reports Stock Transactions

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, reports the acquisition of restricted stock units and stock options, along with sales of common stock to cover tax obligations.

Summary

• On March 1, 2024, Natarajan Sethuraman, the Chief Scientific Officer of Entrada Therapeutics, was granted 44,100 restricted stock units (RSUs) and 66,800 stock options.
• The RSUs vest in four equal installments on March 1st of 2025, 2026, 2027, and 2028.
• The stock options vest 25% on March 1, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, fully vesting on March 1, 2028.
• From March 4-5, 2024, Sethuraman sold a total of 2,266 shares of common stock to cover tax withholding obligations related to the vesting of previously granted RSUs.
• The sales occurred in multiple transactions at weighted average prices ranging from $12.28 to $13.37 per share.
• Following these transactions, Sethuraman directly owns 209,032 shares of common stock and 66,800 stock options.

Sentiment

Score: 6

Explanation: The document primarily reports routine transactions. The grant of RSUs and options is a positive sign, but the sale of shares, even for tax purposes, tempers the overall sentiment.

Positives

• The grant of RSUs and stock options to the Chief Scientific Officer suggests the company is incentivizing long-term performance and retention.
• The vesting schedules for both RSUs and stock options are spread out over several years, aligning the executive's interests with the long-term success of the company.

Negatives

• The sale of shares by the Chief Scientific Officer, even for tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• The vesting of RSUs and stock options is contingent upon the Reporting Person remaining an employee or service provider of the Issuer through the vesting dates.
• Fluctuations in the stock price could impact the value of the RSUs and stock options, affecting the executive's compensation and potentially their motivation.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders, potentially influencing short-term stock price fluctuations.
• Employees may view the grant of RSUs and stock options as a positive sign of the company's commitment to its leadership.

Key Dates